Literature DB >> 22715258

Adrenalectomy to treat reactivated chronic hepatitis B infection in a patient with a steroid-secreting adrenal tumour.

P J Smith1, D Suri.   

Abstract

We present a case of reactivation of chronic hepatitis B virus (HBV) infection by a steroid-producing adrenal tumour. The tumour caused a reactivation and subsequent flare of the patients' HBV. The adrenal tumour was treated with an adrenalectomy and as a consequence the patients' transaminitis and viral load fell rapidly without the need for any additional hepatitis B treatment. The role of hepatitis B and steroid priming is discussed and the possible immunological mechanisms that underpin this phenomenon.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22715258      PMCID: PMC3062063          DOI: 10.1136/bcr.11.2010.3508

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

Review 1.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

2.  A randomised double-blind placebo-controlled trial of prednisolone therapy in HBeAg and HBV DNA positive Chinese patients with chronic active hepatitis B.

Authors:  S D Lee; M J Tong; J C Wu; H C Lin; Y T Tsai; K J Lo
Journal:  J Hepatol       Date:  1991-03       Impact factor: 25.083

3.  A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial.

Authors:  J H Hoofnagle; G L Davis; S C Pappas; R G Hanson; M Peters; M I Avigan; J G Waggoner; E A Jones; L B Seeff
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

4.  Effect of short-term prednisone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis.

Authors:  J Rakela; A G Redeker; B Weliky
Journal:  Gastroenterology       Date:  1983-05       Impact factor: 22.682

5.  Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B.

Authors:  Y F Liaw; S L Tsai; R N Chien; C T Yeh; C M Chu
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

6.  Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

Authors:  Winnie Yeo; Tung C Chan; Nancy W Y Leung; Wai Y Lam; Frankie K F Mo; Miu Ting Chu; Henry L Y Chan; Edwin P Hui; Kenny I K Lei; Tony S K Mok; Paul K S Chan
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Submassive liver necrosis in a hepatitis B carrier with Cushing's syndrome.

Authors:  Pei-Ling Tsou; Hsuan-Shu Lee; Yung-Ming Jeng; Tien-Shang Huang
Journal:  J Formos Med Assoc       Date:  2002-02       Impact factor: 3.282

8.  Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B.

Authors:  G H Scullard; C I Smith; T C Merigan; W S Robinson; P B Gregory
Journal:  Gastroenterology       Date:  1981-12       Impact factor: 22.682

9.  Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells.

Authors:  C K Chou; L H Wang; H M Lin; C W Chi
Journal:  Hepatology       Date:  1992-07       Impact factor: 17.425

10.  Effects of short-term, high-dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis.

Authors:  P V Nair; M J Tong; D Stevenson; D Roskamp; C Boone
Journal:  Liver       Date:  1985-02
View more
  2 in total

1.  A case of acute exacerbation of chronic hepatitis C during the course of adrenal Cushing's syndrome.

Authors:  Takahiro Osuga; Koji Miyanishi; Kota Hamaguchi; Shingo Tanaka; Hiroyuki Ohnuma; Kazuyuki Murase; Kohichi Takada; Junji Kato
Journal:  Clin Case Rep       Date:  2022-02-02

2.  Case reports of latent HBV hepatitis in patients after neurosurgical treatment for hypothalamic and pituitary tumors.

Authors:  Kuniyasu Niizuma; Yoshikazu Ogawa; Takayuki Kogure; Teiji Tominaga
Journal:  BMC Infect Dis       Date:  2020-03-18       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.